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Type 2 diabetes mellitus (T2DM) seems to be a risk 
factor for acquiring the new coronavirus infection. 
Indeed, T2DM and hypertension have been identified 
as the most common comorbidities for other corona-
virus infections, such as severe acute respiratory syn-
drome (SARS) and Middle East respiratory syndrome 
(MERS-CoV)1. According to several reports, includ-
ing those from the Centers for Disease Control and 
Prevention (CDC), patients with T2DM and the meta-
bolic syndrome might have up to ten-times greater risk of 
death when they contract COVID-19 (CDC coronavirus 
reports). Although T2DM and the metabolic syndrome 
increase the risk of more severe symptoms and mortality 
in many infectious diseases, there are some additional 
specific mecha nistic aspects in coronavirus infections 
that require separate consideration, which will have clini-
cal consequences for improved management of patients 
who are severely affected.
Hyperglycaemia and a diagnosis of T2DM are inde-
pendent predictors of mortality and morbidity in patients 
with SARS1. This finding could be due to these pati-
ents having a state of metabolic inflammation that pre-
disposes them to an enhanced release of cytokines. For 
COVID-19, a cyto kine storm (that is, greatly elevated 
levels of inflammatory cytokines) has been implicated in 
the multi-organ failure in patients with severe disease3.
Metabolic inflammation will also compromise the 
immune system, reducing the body’s ability to tackle 
the infection, impairing the healing process and prolon-
ging the recovery. An animal model demonstrated that 
comorbid T2DM results in immune dysregulation and 
enhances disease severity following MERS-CoV infec-
tion2. In this work, diabetic mice expressing the human 
DPP4 (resulting in MERS-CoV susceptibility) exhibited 
an altered profile of cytokines, with increased expres-
sion of IL-17α following infection. These data support 
the hypothesis that the combination of coronavirus 
infection and T2DM triggers a dysregulated immune 
response, resulting in a more aggravated and prolonged 
lung pathology2.
A direct endocrine link
The coronavirus SARS-CoV-2 (which causes COVID-19) 
enters human cells via the envelope spike glycoprotein, 
which is also responsible for host-to-host transmission4. 
This glycoprotein, which is found on the surface of the 
virus, binds to the ectoenzyme angiotensin-converting 
enzyme 2 (ACE2; located on human cells) to gain entry 
into the cell. In addition, the cellular serine protease 
TMPRSS2 is required to prime viral entry via ACE24.
In the respiratory system, ACE2 has the function of 
degrading angiotensin II into angiotensin 1–7 and acts 
as a key regulatory point for the angiotensin system. 
When ACE1 activity is increased and ACE2 inhibited, 
intact angiotensin II acts via the angiotensin 1 receptor 
(AT1R) or AT2R to exert pro-inflammatory responses 
and stimulate aldosterone secretion; these effects not 
only increase blood pressure and potentially cause hypo-
kalaemia, but will also increase vascular permeability 
locally, increasing the risk of respiratory distress syn-
drome. By contrast, angiotensin 1–7 acts on the Mas 
receptor pathway, which leads to anti-inflammatory 
and anti-fibrotic responses that would be favourable to 
the recovery of patients with COVID-195. It could be 
postu lated that individuals with more severe COVID-19 
have an imbalance in the activation of these pathways, 
with an increase in the activation of AT1R and AT2R, 
which could be the case in T2DM, hypertension and 
insulin-resistant states.
A direct metabolic link
In addition to a link between coronavirus infection and 
hypertension, there seems to be a direct link to T2DM. 
In the pancreas, binding of the SARS coronavirus 
(SARS-CoV, which causes SARS) to its receptor, ACE2, 
damages islets and reduces insulin release6. In one study, 
patients with SARS who had no history of T2DM and 
received no steroid treatment were compared with their 
healthy siblings during a 3-year follow-up period. More 
than 50% of the patients in the study became diabetic 
during hospitalization for the SARS-CoV infection. 
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After 3 years of recovery from the viral infection, 
only 5% of patients remained diabetic6. As the human 
endocrine pancreas expresses ACE2, the coronavirus 
might enter islets and cause acute β-cell dysfunction, 
leading to acute hyperglycaemia and transient T2DM6. 
More importantly, evidence in diabetic mice demon-
strated that ACE2 activity levels were enhanced in 
the pancreas7. This finding suggests that patients with 
T2DM might be particularly vulnerable to a corona-
virus infection. Likewise, T2DM induces expression of 
angiotensin-converting enzymes in other tissues, includ-
ing lung, liver and heart7, which explains why T2DM 
can contribute mechanistically to multi-organ failure in 
SARS-CoV infections.
Immediate clinical consequences
Based on the data discussed here, it is evident that 
optimal metabolic control of T2DM and associated 
metabolic parameters in patients with COVID-19 is 
mandatory. This is not only relevant because of the 
obvious danger and increased risk of complications for 
patients with T2DM and a severe infectious disease, but 
also because this approach might help the treatment of 
all patients with COVID-19.
Antidiabetic medications, such as GLP1 agonists, 
that improve the metabolic function and induce the 
activity of the protective ACE2 and Mas receptor path-
ways might have the advantage of ameliorating glucose 
metabolism and blood pressure, and also preventing 
coronaviruses from entering cells as a result of compet-
itive binding to ACE2. This effect might help to pro-
tect and restore pulmonary function5. Likewise, early 
treatment with angiotensin II receptor blockers (such 
as losartan or telmisartan) or, more directly, recombi-
nant ACE2, might be useful to enhance the ACE2 and 
Mas system in preference to the pathways mediated by 
angiotensin receptors. This approach would enable the 
combination of an antidiabetic, anti-inflammatory and 
antiviral effect.
Finally, the synthetic protease inhibitor camustat, 
which blocks the serine protease TMPRSS2 required 
for ACE2-mediated coronavirus entry into the cells4, 
also reverses dyslipidaemia and hyperglycaemia8. The 
intriguing link between coronavirus infections and these 
endocrine and metabolic pathways will have an impor-
tant effect on the general medical management of severe 
COVID-19. Glucocorticoids that have been helpful in the 
treatment of acute respiratory distress syndrome might 
not be indicated in patients with coronavirus infection. 
Glucocorticoids not only aggravate metabolic control, 
but also attenuate angiotensin 1–7 and Mas receptor 
expression9. Hence, they might have a limited role in the 
management of patients with COVID-19. By contrast, 
the anti-rheumatic drug hydroxychloroquine, which is 
now widely used in many centres around the world treat-
ing patients with COVID-19, has also attracted interest 
as a potential therapeutic intervention for patients with 
T2DM10. At this point, it is unclear whether hydroxy-
chloroquine in addition to anti-inflammatory and 
antidiabetic drugs will also directly interfere with the 
coronavirus–ACE2 pathways.
In conclusion, COVID-19 is not primarily a metabolic 
disease, but metabolic control of glucose, lipid levels and 
blood pressure are key in these patients. This approach 
is important to address the well-established metabolic 
and cardiovascular complications of this primary comor-
bidity. Moreover, effective control of these metabolic 
parameters might represent a specific and mechanistic 
approach to prevent and ameliorate the acute effects of 
this virus by reducing the local inflammatory response 
and blocking its entry into cells.
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